Park Circle Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Park Circle Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Hold	2,764	–	–	1.17%	21
2026 Q1	$1.23M	Hold	2,764	–	–	1.14%	22
2025 Q4	$1.25M	Hold	2,764	–	–	1.08%	24
2025 Q3	$1.08M	Hold	2,764	–	–	0.91%	27
2025 Q2	$1.23M	Hold	2,764	–	–	1.04%	29
2025 Q1	$1.34M	Hold	2,764	–	–	1.18%	27
2024 Q4	$1.11M	Hold	2,764	–	–	0.99%	31
2024 Q3	$1.29M	Hold	2,764	–	–	1.13%	29
2024 Q2	$1.3M	Hold	2,764	–	–	1.24%	26
2024 Q1	$1.16M	Hold	2,764	–	–	1.06%	27
2023 Q4	$1.12M	Buy	+2,764	New	+$1.02M	1.01%	28

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Park Circle Company's VRTX Position: Q2 2026 in Review

Park Circle Company held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 2,764 shares worth $1.37M. The position accounts for 1.17% of the portfolio, ranked #21.

Park Circle Company first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Park Circle Company held 2,764 shares of Vertex Pharmaceuticals worth $1.37M as of Q2 2026.
Park Circle Company left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 1.17% of Park Circle Company's portfolio in Q2 2026, its #21 holding.
Park Circle Company first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Park Circle Company's 13F filing for Q2 2026, filed 13 Aug 2026.